CareCost Prior authorization
Required
Check what the payer requires before you schedule Rituxan.
Prior authorization · preferred product · clinical criteria · dosing · site of care
25 payer policy sets · source-linked · reviewed August 2026
Aetna + Rheumatoid arthritis is shown as a live example until you choose a payer.
This payer requires an approval on file before Rituxan is purchased or infused for this member.
Precertification of rituximab (Rituxan), rituximab-abbs (Truxima), rituximab-arrx (Riabni), rituximab-pvvr (Ruxience), or rituximab / hyaluronidase (Rituxan Hycela) is required of all Aetna participating providers
Adults with moderately to severely active RA; prior biologic or targeted synthetic drug required, or biomarker-confirmed disease with MTX trial failure
For adults who have previously received a biologic or targeted synthetic drug (e.g., Rinvoq, Xeljanz) indicated for the treatment of moderately to severely active rheumatoid arthritis.
What opens in CareCost
Aetna · Rituxan · Rheumatoid arthritis
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Aetna · Rituxan · Rheumatoid arthritis
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Rituxan coverage requirements across 25 payer policy sets.
Aetna · Anthem / Elevance · Cigna · UnitedHealthcare · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →19 of 25 commercial payers require prior authorization. Prior-treatment, preferred-product and site-of-care rules vary by plan.
19 require PA · 25 have clinical criteria · 7 restrict site of care · 21 carry a preferred-product rule
Many commercial payers require approval before rituximab is purchased or infused.
Coverage depends on the diagnosis included in the payer’s rituximab policy.
Plans may require documentation of previous therapies, failures, contraindications or preferred alternatives.
Some plans prefer a biosimilar or require an exception before covering Rituxan.
The ordered dose and frequency may need to match diagnosis-specific policy criteria.
Some plans restrict specialty-drug infusions to approved sites or settings.
Certain diagnoses may require treatment by, or consultation with, a particular specialist.
In this corpus, 21 of the 25 payers carry a preferred-product rule for rituximab, and most name a biosimilar (Truxima, Ruxience or Riabni) ahead of Rituxan. Some require two of the three to fail first.
| Payer | Preferred products named | What the policy requires |
|---|---|---|
| BCBS Michigan | Riabni, Ruxience, Truxima | “Preferred products: Riabni, Ruxience, and Truxima” |
| BCBS Minnesota | Ruxience, Truxima, Riabni | “a contraindication, intolerance, or failure to Ruxience, Truxima, AND Riabni prior to the consideration of another rituximab product” |
| Cigna | Truxima, Riabni, Ruxience | “has tried ALL of the following: Truxima, Riabni, and Ruxience” |
| BCBS Massachusetts | Two preferred biosimilars (unnamed in the policy text) | “Rituxan or Riabni approvals require the use of two preferred biosimilars except where noted” |
| HMSA | Riabni, Truxima | “Coverage for a non-preferred product is provided when the member has had a documented intolerable adverse event to the preferred products, Riabni and Truxima.” |
| BCBS FEP | Rituxan, Rituxan Hycela, Riabni | “Non-preferred products only: Inadequate treatment response, intolerance, or contraindication to ONE of the preferred products (Riabni, Rituxan, Rituxan Hycela)” |
For rheumatoid arthritis, the most common prerequisite in this corpus is failure of one or more TNF antagonists. Rituximab is an anti-CD20 monoclonal antibody, not a TNF blocker, so payers ask for that class to have failed before rituximab starts. A conventional DMARD trial, usually methotrexate, for about three months is the other common shape.
GPA, MPA and pemphigus vulgaris use a different shape. BCBS Arkansas requires “inadequate response or is intolerant to initial treatment with azathioprine, methotrexate, and/or mycophenolate” for GPA and MPA, and for pemphigus vulgaris that the patient “is unresponsive to conventional therapy (e.g., systemic corticosteroids and immunosuppressive agents)”.
No prior authorization for Part B rituximab. Coverage follows the diagnosis codes in the Medicare policy — the governing local coverage determinations are published in the CMS Medicare Coverage Database, and a MAC can differ from its neighbour on the same drug.
At 19 of the 25 payers on file for J9312, yes, and all 25 apply clinical coverage criteria before treatment. Check this patient’s payer →
Clinical, dosing, product and site-of-care rules can still apply beyond the diagnosis. Rheumatoid arthritis is a covered indication under many rituximab policies. Check coverage →
It depends on the payer. Some policies prefer another rituximab product or require an exception before Rituxan is covered. Check preferred-product rules →
CareCost turns the applicable payer policy for Rituxan (J9312) into a patient-level checklist showing each requirement, what to confirm, and the source language supporting it. Open patient clearance →
Data current: payer policies Aug 2026 · reviewed dates come from each payer
Payer medical and specialty-drug policies · prior-authorization criteria · site-of-care policies · preferred-product policies. Medicare coverage from the CMS Medicare Coverage Database. Every CareCost requirement links back to its source policy.